vs
JBG SMITH Properties（JBGS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是JBG SMITH Properties的1.1倍（$139.1M vs $127.6M），VERACYTE, INC.净利率更高（20.6% vs -18.1%，领先38.7%），VERACYTE, INC.同比增速更快（21.5% vs 5.7%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs -2.9%）
JBG SMITH Properties是一家总部位于马里兰州贝塞斯达的上市房地产投资信托公司，专注于持有并运营房地产资产，是美国商业地产领域的专业运营机构，面向市场提供多元化的不动产投资与管理服务。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
JBGS vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.1倍
$127.6M
营收增速更快
VCYT
高出15.8%
5.7%
净利率更高
VCYT
高出38.7%
-18.1%
两年增速更快
VCYT
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $127.6M | $139.1M |
| 净利润 | $-23.0M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | — | 16.3% |
| 净利率 | -18.1% | 20.6% |
| 营收同比 | 5.7% | 21.5% |
| 净利润同比 | 57.1% | — |
| 每股收益（稀释后） | $-0.32 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JBGSVCYT
| Q1 26 | $127.6M | $139.1M | ||
| Q4 25 | $127.6M | $140.6M | ||
| Q3 25 | $123.9M | $131.9M | ||
| Q2 25 | $126.5M | $130.2M | ||
| Q1 25 | $120.7M | $114.5M | ||
| Q4 24 | $130.8M | $118.6M | ||
| Q3 24 | $136.0M | $115.9M | ||
| Q2 24 | $135.3M | $114.4M |
净利润JBGSVCYT
| Q1 26 | $-23.0M | $28.7M | ||
| Q4 25 | $-45.5M | $41.1M | ||
| Q3 25 | $-28.6M | $19.1M | ||
| Q2 25 | $-19.2M | $-980.0K | ||
| Q1 25 | $-45.7M | $7.0M | ||
| Q4 24 | $-59.9M | $5.1M | ||
| Q3 24 | $-27.0M | $15.2M | ||
| Q2 24 | $-24.4M | $5.7M |
毛利率JBGSVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率JBGSVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | -47.5% | 26.4% | ||
| Q3 25 | -27.5% | 17.4% | ||
| Q2 25 | -18.4% | -4.0% | ||
| Q1 25 | -44.7% | 2.5% | ||
| Q4 24 | -53.6% | 3.5% | ||
| Q3 24 | -22.4% | 10.4% | ||
| Q2 24 | -24.3% | 4.0% |
净利率JBGSVCYT
| Q1 26 | -18.1% | 20.6% | ||
| Q4 25 | -35.7% | 29.3% | ||
| Q3 25 | -23.1% | 14.5% | ||
| Q2 25 | -15.2% | -0.8% | ||
| Q1 25 | -37.9% | 6.2% | ||
| Q4 24 | -45.8% | 4.3% | ||
| Q3 24 | -19.8% | 13.1% | ||
| Q2 24 | -18.0% | 5.0% |
每股收益（稀释后）JBGSVCYT
| Q1 26 | $-0.32 | $0.35 | ||
| Q4 25 | $-0.76 | $0.50 | ||
| Q3 25 | $-0.48 | $0.24 | ||
| Q2 25 | $-0.29 | $-0.01 | ||
| Q1 25 | $-0.56 | $0.09 | ||
| Q4 24 | $-0.70 | $0.07 | ||
| Q3 24 | $-0.32 | $0.19 | ||
| Q2 24 | $-0.27 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.3B |
| 总资产 | $4.3B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JBGSVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $75.3M | $362.6M | ||
| Q3 25 | $64.4M | $315.6M | ||
| Q2 25 | $61.4M | $219.5M | ||
| Q1 25 | $81.3M | $186.1M | ||
| Q4 24 | $145.8M | $239.1M | ||
| Q3 24 | $137.0M | $274.1M | ||
| Q2 24 | $163.5M | $235.9M |
股东权益JBGSVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.9B | $1.2B | ||
| Q2 24 | $2.0B | $1.1B |
总资产JBGSVCYT
| Q1 26 | $4.3B | $1.4B | ||
| Q4 25 | $4.4B | $1.4B | ||
| Q3 25 | $4.4B | $1.4B | ||
| Q2 25 | $4.5B | $1.3B | ||
| Q1 25 | $4.7B | $1.3B | ||
| Q4 24 | $5.0B | $1.3B | ||
| Q3 24 | $5.2B | $1.3B | ||
| Q2 24 | $5.3B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $35.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流JBGSVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $73.3M | $52.6M | ||
| Q3 25 | $8.9M | $44.8M | ||
| Q2 25 | $18.8M | $33.6M | ||
| Q1 25 | $12.9M | $5.4M | ||
| Q4 24 | $129.4M | $24.5M | ||
| Q3 24 | $26.4M | $30.0M | ||
| Q2 24 | $23.8M | $29.6M |
自由现金流JBGSVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M |
自由现金流率JBGSVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% |
资本支出强度JBGSVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% |
现金转化率JBGSVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBGS
| Property rental | $105.9M | 83% |
| Third-party real estate services, including reimbursements | $17.2M | 13% |
| Other revenue | $4.5M | 4% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
